Resources

Help yourself to our online catalogue of useful information, including annual reports, scientific and clinical trial publications, infographics and more.

Filter by language:
Filter by category:
Search resources:
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Protocol
22 Dec 2020

Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols

MDGH-MOX-3001: Safety and efficacy of annual or biannual doses of moxidectin or ivermectin for onchocerciasis​(Target: approx. 1,000 participants)​

Protocol
22 Dec 2020

Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols

MDGH-MOX-3002: Safety of a single dose of moxidectin compared with ivermectin in individuals living in onchocerciasis-endemic areas. (Target: approx. 12,500 participants)  

Annual Report
22 Dec 2020

2020 Annual Report

Lorem Ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Peer-reviewed publication
22 Dec 2020

Phase 3 Clinical Trials: Moxidectin for Onchocerciasis

Opoku NO, Bakajika DK, Kanza EM, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392(10154):1207-1216

Peer-reviewed publication
22 Dec 2020

Phase 1 Clinical Trials: Moxidectin

Korth-Bradley JM, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L. Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin. Clin Pharmacol Drug Dev. 2012;1(1):32-37.

Peer-reviewed publication
22 Dec 2020

Phase 1 Clinical Trials: Moxidectin

Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother.2011;55(11):5200-5204.

Protocol
22 Dec 2020

Onchocerciasis Review

Milton P, Hamley JID, Walker M, Basanez MG. Moxidectin: an oral treatment for human onchocerciasis. Expert Rev Anti Infect Ther. 2020:1-15. 10.1080/14787210.2020.1792772

Peer-reviewed publication
22 Dec 2020

Phase 2 Clinical Trials: Moxidectin for Onchocerciasis

Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953.

Peer-reviewed publication
22 Dec 2020

Phase 1 Clinical Trials: Moxidectin

Kinrade SA, Mason JW, Sanabria CR, et al. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. Clin Transl Sci. 2018;11(6):582-589.

Peer-reviewed publication
22 Dec 2020

Modelling

Turner HC, Walker M, Attah SK, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015;8:167.

Peer-reviewed publication
22 Dec 2020

Onchocerciasis Review

Boussinesq M, Fobi G, Kuesel AC. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Health. 2018;10(suppl_1):i40-i48.

Peer-reviewed publication
22 Dec 2020

Onchocerciasis Review

Prichard RK, Geary TG. Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2019;10:69-83.

Protocol
22 Dec 2020

Moxidectin in Onchocerciasis: Ongoing Clinical Trial Protocols

MDGH-MOX-1006: A pharmacokinetic and safety study of moxidectin to identify an optimal dose for treatment of children 4 to 11 years (Target: at least 27 participants) ​

Load more